2. Anti-infection
  3. Bacterial Antibiotic
  4. Cefpirome sulfate

Cefpirome sulfate  (Synonyms: HR-810 sulfate)

Cat. No.: HY-B1824 Purity: 99.49%
COA
SDS
Handling Instructions Technical Support

Cefpirome (HR-810) sulfate is a cephalosporin antibiotic that can cross cell membranes and the blood-brain barrier. Cefpirome sulfate binds to penicillin-binding proteins with high affinity, thereby inhibiting bacterial cell wall synthesis. Cefpirome sulfate exhibits bactericidal and growth-inhibitory activities against Gram-negative bacteria, Gram-positive bacteria, and susceptible anaerobic bacteria (including some β-lactamase-producing strains).

For research use only. We do not sell to patients.

Cefpirome sulfate

Cefpirome sulfate Chemical Structure

CAS No. : 98753-19-6

Size Price Stock Quantity
250 mg In-stock
500 mg In-stock
1 g In-stock
5 g In-stock
10 g   Get quote  
50 g   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Cefpirome sulfate:

Cefpirome sulfate Related Antibodies

Top Publications Citing Use of Products

1 Publications Citing Use of MCE Cefpirome sulfate

View All Antibiotic Isoform Specific Products:

View All Isoforms
Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Cefpirome (HR-810) sulfate is a cephalosporin antibiotic that can cross cell membranes and the blood-brain barrier. Cefpirome sulfate binds to penicillin-binding proteins with high affinity, thereby inhibiting bacterial cell wall synthesis. Cefpirome sulfate exhibits bactericidal and growth-inhibitory activities against Gram-negative bacteria, Gram-positive bacteria, and susceptible anaerobic bacteria (including some β-lactamase-producing strains)[1][2][3].

IC50 & Target

β-lactam

 

In Vitro

Cefpirome sulfate exhibits excellent in vitro antibacterial activity against most Enterobacteriaceae (including strains resistant to third-generation cephalosporins), methicillin-sensitive staphylococci, and streptococci (including penicillin-resistant Streptococcus pneumoniae). It shows moderate activity against Pseudomonas aeruginosa, variable activity against anaerobes, and weak activity against methicillin-resistant staphylococci and Enterococcus faecalis[1].
Cefpirome sulfate is stable to most plasmid-mediated and chromosome-mediated β-lactamases, except for extended-spectrum SHV enzymes, and retains activity against β-lactamase-producing, third-generation cephalosporin-resistant *Enterobacteriaceae* strains[1].
Cefpirome sulfate exhibits rapid outer membrane permeability to Gram-negative bacteria, as well as high-affinity binding to key penicillin-binding proteins in both Gram-negative and Gram-positive bacteria, which endows it with broad-spectrum antibacterial activity[1].
Cefpirome (18 h) sulfate exhibits mutation prevention concentration (MPC) against Enterobacter cloacae of 1 μg/mL, which defines a narrow mutant selection window between its MIC (0.125 μg/mL) and MPC[2].
Cefpirome (0.06-32 μg/mL; 18-24 h) sulfate potently inhibits clinical isolates of Enterobacteriaceae (with MIC90 ≤ 0.5 μg/mL for most species), exhibits activity against non-glucose-fermenting Gram-negative bacilli, and shows activity against both oxacillin-susceptible and Oxacillin (HY-B0925A)-resistant staphylococci (the MIC90 is 1 μg/mL for Oxacillin-susceptible Staphylococcus aureus and 16 μg/mL for Oxacillin-resistant Staphylococcus aureus). Only the MIC against coagulase-negative staphylococci shows a slight salt-dependent increase[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cefpirome sulfate Related Antibodies
Parmacokinetics
Species Dose Route Vss T1/2 CL
Rat[2] 0.4, 0.8, 1.6, 3.1, 6.3, 12.5, 25, 50 mg/kg i.m. 0.36 L/kg 1.22-1.63 h 1.23-1.64 mL/min
In Vivo

Cefpirome sulfate (0.37 mg/kg) exhibits potent in vivo activity against MSSA-induced acute lethal systemic infection in mice, with an ED50 of 0.37 mg/kg[1].
Cefpirome sulfate (0.025-1.56 mg/kg) demonstrates high in vivo efficacy against a range of bacterial systemic infections in mice, with ED50 values ranging from 0.025 to 1.56 mg/kg[1].
Cefpirome sulfate shows in vivo activity against Pseudomonas aeruginosa-induced systemic infection in mice, but is approximately 2-fold less potent than ceftazidime[1].
Cefpirome sulfate exhibits in vivo efficacy against Acinetobacter spp.-induced systemic infection in mice[1].
Cefpirome sulfate (15.4 mg/kg) is highly bactericidal against Klebsiella pneumoniae-induced pneumonia in mice, with an ED50 of 15.4 mg/kg at 18 hours[1].
Cefpirome (0.4-50 mg/kg b.i.d.; intramuscular injection; every 12 hours; 18 days) sulfate results in dose-dependent survival of rats with K. pneumoniae pneumonia and only minimal selection of stable derepressed ampD-mutated E. cloacae mutants from intestinal flora[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: RP/AEur/RijHsd rats (male, 11-15 weeks old, 250-350 g, left-sided unilateral pneumonia induced via tracheal cannulation with Klebsiella pneumoniae ATCC 43816)[2]
Dosage: 0.4 mg/kg b.i.d.; 0.8 mg/kg b.i.d.; 1.6 mg/kg b.i.d.; 3.1 mg/kg b.i.d.; 6.3 mg/kg b.i.d.; 12.5 mg/kg b.i.d.; 25 mg/kg b.i.d.; 50 mg/kg b.i.d.
Administration: intramuscular injection; every 12 hours; 18 days
Result: Achieved 45% survival rate at day 43 post-inoculation with 3.1 mg/kg b.i.d.
dose.
Achieved 60% survival rate at day 43 post-inoculation with 6.3 mg/kg b.i.d.
dose.
Achieved 100% survival rate at day 43 post-inoculation with 12.5 mg/kg b.i.d.
dose.
Resulted in 50% survival at 12.5 mg/kg/day dose and 90% survival at 25 mg/kg/day dose.
Reduced cefpirome-susceptible intestinal E.
cloacae counts in a dose-dependent manner, with significant reductions (p < 0.05) observed at day 36 for 25 and 50 mg/kg b.i.d., day 29 for 6.3 and 12.5 mg/kg b.i.d., and day 22 for 3.1 mg/kg b.i.d.
compared to pre-treatment levels.
Showed a significant negative correlation between %fT>MIC and log10 cfu counts of susceptible E.
cloacae at days 7, 14, 22, and 29, with each 1% increase in %fT>MIC correlating with a 0.056 reduction in log10 cfu (95% CI: -0.092 to -0.0202 at day 7).
Detected cefpirome-resistant E.
cloacae mutants (MIC ≥ 2 μg/mL, stable after 5 subcultures in antibiotic-free broth) in only 4 rats: 2 treated with 50 mg/kg b.i.d.
(550 cfu/g and 440 cfu/g at day 7, declining to 20 cfu/g and remaining at 400 cfu/g by day 43, respectively), 1 treated with 25 mg/kg b.i.d.
(180 cfu/g at day 7, increasing to 1×103 cfu/g by day 43), and 1 treated with 12.5 mg/kg b.i.d.
(500 cfu/g at day 43).
Molecular Weight

612.66

Formula

C22H24N6O9S3
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1[C@@H](NC(/C(C2=CSC(N)=N2)=N\OC)=O)[C@@]3([H])SCC(C[N+]4=CC=CC5=C4CCC5)=C(C(O)=O)N13.O=S(O)([O-])=O
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility
In Vitro: 

H2O : < 0.1 mg/mL (insoluble)

DMSO : < 1 mg/mL (insoluble or slightly soluble)

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
Purity & Documentation

Purity: 99.49%

SDS (396 KB)

COA (260 KB) HNMR (329 KB) LCMS (95 KB)

Handling Instructions (2659 KB)
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Cefpirome sulfate Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cefpirome98753-19-6HR-810HR810HR 810BacterialAntibioticEnterobacter cloacaeGram-negative bacteriamouse models of pneumoniabacterial cell wall synthesisanaerobic bacteriamouse models of systemic infectionKlebsiella pneumoniaepenicillin binding proteinsPseudomonas aeruginosaGram-positive bacteriaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Cefpirome sulfate
Cat. No.:
HY-B1824
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (396 KB) Français - FR (396 KB) Deutsch - DE (396 KB) Norwegian - NO (396 KB) Español - ES (396 KB) Swedish - SV (396 KB) Italian - IT (396 KB) Korean - KR (396 KB) Portuguese - PT (396 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.